Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety of the combination of SOM230
and RAD001, as well as determine the highest dose of this combination that can be given to
people safely. SOM230 is an investigational drug that is similar to Sandostatin LAR.
Sandostatin is an approved drug for the use of treating symptoms of neuroendocrine tumors.
SOM230 has shown to be effective in patients who have become resistant to Sandostatin and may
also stop cancer cells from growing. RAD001 is an investigational drug that also may stop
cancer cells from growing.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital Novartis